Edwards Carl

 

Ass. Prof. Carl Edwards – USA

                                    
Associate Professor of Medicine, Department of Dermatology, Psoriasis and Cutaneous Inflammation Research Laboratory, University of Colorado Denver, Anschutz Medical Center (UCD, AMC).
Chief Scientific Officer and Co-Founder, Western States Biopharmaceuticals, Inc. Bioscience Park Center.
Professor, Functional Genomics and Immunology, Chinese National Human Genome Center, Beijing.
 
Department of Dermatology Psoriasis and Cutaneous Inflammation Research Laboratory University of Colorado Denver, Anschutz Medical Campus Building RC1 South, 12801 East 17th Avenue, Room L18-4125 Mail Stop 8127 Aurora, CO 80045 U.S.A.
Office Phone: (303) 724-4043
Department Fax: (303) 724-4048
 
e-mail: Carl.Edwards@ucdenver.edu
 
Professional Education:
Post-Doctoral – University of Indiana School of Medicine, Indianapolis, IN, and Terre Haute, IN 1989-1990; Focus: Pathogenesis of Autoimmunity; Ph.D. – Department of Veterinary Pathobiology and Animal Sciences, University of Illinois, Urbana-Champaign, IL, 1989; Focus: Immunophysiology; M.A. – Department of Biology, University of Colorado, Denver, CO, 1984; Focus: Pathogenesis of Mycobacterium intracellulare; 
B.S. – Department of Microbiology, Colorado State University, Fort Collins, CO, 1980: Focus: Oncogenic viruses
 
Major Scientific Interests:
1) Pathogenesis of Cutaneous Inflammation: The study of the molecular and cellular immunological mechanisms of inflammatory cutaneous diseases, including Atopic Dermatitis, Psoriasis and Psoriatic Arthritis;
2) Cytokine Regulation: The molecular regulation of major proinflammatory cytokines, including tumor necrosis factor-alpha (TNFα), interleukin-1b (1L1b), Interleukin-32 gamma (IL32γ), and interleukin-39 (IL39β);
3) Translational Medicine: The identification of surrogate and biochemical markers of autoimmune disease using precision gene expression analysis;
4) Current ongoing research: My research is focused on cell-cell immunological synapse interactions between activated, memory T lymphocytes and antigen presenting cells/macrophages/dendritic cells; the elucidation of the mechanisms of suppression by lineages of human regulatory T cells, and the role of pleotrophic chemokines in the migration of autoreactive T cells to the sites of cutaneous inflammation;
5) Overall research aim: The research aim of my research laboratory is to identify, using cutting edge functional genomics, molecular and cellular technology platforms, novel T-cell membrane proteins that promote proinflammatory cytokine production and the initiation of chronic autoinflammatory diseases in the joints and skin;
 
Professional Society Memberships
§ 19th Joint Conf of US-Japan Panels on Tuberculosis and Leprosy, Bethesda, MD, (1984);
§ International Cytokine Society, (1994- );
§ Society for Investigative Dermatology (SID), (2003- );
§ American College of Rheumatology (ACR), (1991- );
§ American Association of Pharmaceutical Scientists (AAPS), (1990- );
§ Sigma Xi-The Scientific Research Society, (1986- );
§ Society for Leukocyte Biology (RES), (1986- );
§ American Association for the Advancement of Science (AAAS), (1983- );
§ American Association of Immunologists (AAI), (1985- );
§ American Society for Microbiology (ASM), (1984 – );
§ American Skin Association, (2005 – );
§ American Academy of Dermatology, (2005 – );
§ American Dermatologic Association, (2005 – );
§ Colorado Dermatologic Society, (2005 – );
§ The Brendan Society, (2007 – );
§ National Advisory Committee (RCMI External Advisory Subcommittee); Florida A&M University, (2007-2013);
 
Research Support – Active:
1. NIAMS P30-AR057212 “Molecular Analysis, Modeling and Correction of Skin Diseases” NIH NIAMS SDRC Center for Dermatology Research (PI Norris) 06/01/11 – 05/31/12
2. The Interleukin Foundation, Denver, CO, USA 09/01/11 – 08/31/12 “Elevated Interleukin 32γ (IL32γ) in Activated Human Th22 Memory T cells”
3. Western States Biopharmaceuticals, Inc., Aurora, CO, USA (PI Edwards) 04/01/10 – 12/31/12 “Identification and Characterization of Human Native Soluble EMMPRIN Inhibitor”
 
Research Support – Pending:
1. Chinese Natural National Science Foundation (PI Zhou) 10/01/11 – 09/30/13
2. NIAMS 1 R01 AR062411 – 01 07/01/12 – 06/31/17 “Immunophilin FKBP52 as a Central Mediator between Innate and Adaptive Immunity”
3. NIAMS 1 R43 AR-12-006 011-02 06/01/2012- 05/31/2013 “Phage Display Monoclonal and Bispecific Antibodies for Alopecia Universalis”
4. NIH R43 AR062411-01 A1 07/01/2012-06/30/2013 “Development of Anti-Interleukin-39 Fully-Human mAbs for Autoimmune Diseases”
5. NIAMS 1 R43 AR062411 – 01 10/01/12 – 09/30/13 “Identification of the Interleukin-39 Receptor for Inflammatory Diseases”
 
Conference Activities and Bibliography in pdf
 
 
 


CONTENT

SERVICES

Other Resources

Our Dermatology Online

Home
Current Issue
All Issues
Instruction for authors
Submit Manuscripts
Ethics in Publishing
For Reviewers
Readers
About
Editors & Publishers 
Statistics
Copyright
Contact Us